Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
1 other identifier
expanded_access
N/A
0 countries
N/A
Brief Summary
The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 22, 2024
CompletedFirst Posted
Study publicly available on registry
May 29, 2024
CompletedJuly 24, 2025
July 1, 2025
May 22, 2024
July 23, 2025
Conditions
Keywords
Interventions
Fosmanogepix solution for infusion, 20 mg/mL for intravenous administration
Fosmanogepix 400 mg tablets for oral administration
Eligibility Criteria
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 22, 2024
First Posted
May 29, 2024
Last Updated
July 24, 2025
Record last verified: 2025-07